These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34789584)

  • 1. Design, Synthesis, and Functional Evaluation of 1, 5-Disubstituted Tetrazoles as Monoamine Neurotransmitter Reuptake Inhibitors.
    Paudel S; Wang S; Kim E; Kundu D; Min X; Shin CY; Kim KM
    Biomol Ther (Seoul); 2022 Mar; 30(2):191-202. PubMed ID: 34789584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple reuptake inhibitors: Design, synthesis and structure-activity relationship of benzylpiperidine-tetrazoles.
    Paudel S; Min X; Acharya S; Khadka DB; Yoon G; Kim KM; Cheon SH
    Bioorg Med Chem; 2017 Oct; 25(20):5278-5289. PubMed ID: 28807575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and in vitro activity of 1,4-disubstituted piperazines and piperidines as triple reuptake inhibitors.
    Paudel S; Acharya S; Yoon G; Kim KM; Cheon SH
    Bioorg Med Chem; 2017 Apr; 25(7):2266-2276. PubMed ID: 28274674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Potent Dopamine-Norepinephrine and Triple Reuptake Uptake Inhibitors Based on Asymmetric Pyran Template and Their Molecular Interactions with Monoamine Transporters.
    Santra S; Kortagere S; Vedachalam S; Gogoi S; Antonio T; Reith MEA; Dutta AK
    ACS Chem Neurosci; 2021 Apr; 12(8):1406-1418. PubMed ID: 33844493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Requirements for Modulating 4-Benzylpiperidine Carboxamides from Serotonin/Norepinephrine Reuptake Inhibitors to Triple Reuptake Inhibitors.
    Paudel S; Kim E; Zhu A; Acharya S; Min X; Cheon SH; Kim KM
    Biomol Ther (Seoul); 2021 Jul; 29(4):392-398. PubMed ID: 34053940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploration of substituted arylpiperazine-tetrazoles as promising dual norepinephrine and dopamine reuptake inhibitors.
    Paudel S; Acharya S; Yoon G; Kim KM; Cheon SH
    Bioorg Med Chem; 2016 Nov; 24(21):5546-5555. PubMed ID: 27647372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and docking study of 4-arylpiperazine carboxamides as monoamine neurotransmitters reuptake inhibitors.
    Paudel S; Sun N; Khadka DB; Yoon G; Kim KM; Cheon SH
    Bioorg Med Chem; 2018 Aug; 26(14):4127-4135. PubMed ID: 30007567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological and behavioral analysis of the effects of some bivalent ligand-based monoamine reuptake inhibitors.
    Tamiz AP; Bandyopadhyay BC; Zhang J; Flippen-Anderson JL; Zhang M; Wang CZ; Johnson KM; Tella S; Kozikowski AP
    J Med Chem; 2001 May; 44(10):1615-22. PubMed ID: 11334571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biaryl analogues of conformationally constrained tricyclic tropanes as potent and selective norepinephrine reuptake inhibitors: synthesis and evaluation of their uptake inhibition at monoamine transporter sites.
    Zhou J; Zhang A; Kläss T; Johnson KM; Wang CZ; Ye YP; Kozikowski AP
    J Med Chem; 2003 May; 46(10):1997-2007. PubMed ID: 12723962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse.
    Froimowitz M; Wu KM; Moussa A; Haidar RM; Jurayj J; George C; Gardner EL
    J Med Chem; 2000 Dec; 43(26):4981-92. PubMed ID: 11150168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors.
    Choi SW; Elmaleh DR; Hanson RN; Fischman AJ
    J Med Chem; 1999 Sep; 42(18):3647-56. PubMed ID: 10479296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Functional Role of Phenethylamine Derivatives in Inhibiting Dopamine Reuptake: Structure-Activity Relationship.
    Kundu D; Zhu A; Kim E; Paudel S; Jang CG; Lee YS; Kim KM
    Biomol Ther (Seoul); 2023 Jan; 31(1):108-115. PubMed ID: 36098044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative contributions of norepinephrine and serotonin transporters to antinociceptive synergy between monoamine reuptake inhibitors and morphine in the rat formalin model.
    Shen F; Tsuruda PR; Smith JA; Obedencio GP; Martin WJ
    PLoS One; 2013; 8(9):e74891. PubMed ID: 24098676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
    Gray DL; Xu W; Campbell BM; Dounay AB; Barta N; Boroski S; Denny L; Evans L; Stratman N; Probert A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6604-7. PubMed ID: 19854053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of cis-(6-benzhydrylpiperidin-3-yl)benzylamine analogues with monoamine transporters: structure-activity relationship study of structurally constrained 3,6-disubstituted piperidine analogues of (2,2-diphenylethyl)-[1-(4-fluorobenzyl)piperidin-4-ylmethyl]amine.
    Kolhatkar RB; Ghorai SK; George C; Reith ME; Dutta AK
    J Med Chem; 2003 May; 46(11):2205-15. PubMed ID: 12747792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.
    Lee KH; Park CE; Min KH; Shin YJ; Chung CM; Kim HH; Yoon HJ; Won-Kim ; Ryu EJ; Shin YJ; Nam HS; Cho JW; Lee HY
    Bioorg Med Chem Lett; 2010 Sep; 20(18):5567-71. PubMed ID: 20724153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and pain-depressed behavior in rats.
    Rosenberg MB; Carroll FI; Negus SS
    J Pain; 2013 Mar; 14(3):246-59. PubMed ID: 23332494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters.
    Zhang S; Fernandez F; Hazeldine S; Deschamps J; Zhen J; Reith ME; Dutta AK
    J Med Chem; 2006 Jul; 49(14):4239-47. PubMed ID: 16821783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationship of novel series of 1,5-disubstituted tetrazoles as cyclooxygenase-2 inhibitors: Design, synthesis, bioassay screening and molecular docking studies.
    Jawabrah Al-Hourani B; Al-Awaida W; Matalka KZ; El-Barghouthi MI; Alsoubani F; Wuest F
    Bioorg Med Chem Lett; 2016 Oct; 26(19):4757-4762. PubMed ID: 27567369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents.
    Dutta AK; Gopishetty B; Gogoi S; Ali S; Zhen J; Reith M
    Eur J Pharmacol; 2011 Dec; 671(1-3):39-44. PubMed ID: 21963455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.